Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Date Issued: March 17, 2016
Reporting Period: Period ending March 2016
Subject: Announcement of results from the VESTRI (SAS115358) paediatric safety study for Advair Diskus (fluticasone propionate/salmeterol).
Key Financial Metrics
This filing is a current report regarding clinical trial results and regulatory compliance. It does not contain financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial indicators.
Material Changes and Clinical Results
The filing details the completion of the VESTRI study, a post-marketing requirement by the US FDA. Key findings include:
- Study Population: 6,250 children aged 4-11 years across 31 countries.
- Primary Endpoint: The study demonstrated non-inferiority of Advair Diskus (FSC) compared to fluticasone propionate (FP) monotherapy regarding the risk of serious asthma-related events (deaths, intubations, or hospitalisations).
- Statistical Data: Hazard Ratio (HR) 1.285 (95% CI 0.726, 2.272), p=0.006. The upper limit of the confidence interval was below the predefined non-inferiority margin of 2.675.
- Event Breakdown: All 48 serious asthma-related events were hospitalisations. There were no asthma-related deaths or intubations in either treatment arm.
- Secondary Observation: A non-statistically significant 14% reduction in the risk of time-to-first asthma exacerbation was observed for FSC compared to FP (HR 0.859).
Outlook, Risks, and Management Commentary
Regulatory Context: VESTRI is the second study GSK conducted as an FDA post-marketing requirement for LABA-containing products. GSK was the only manufacturer to conduct a study in children aged 4-11 years, as it holds the only US license for this age group.
Risks and Safety Warnings: The filing reiterates significant safety warnings associated with Advair Diskus:
- Asthma-Related Death: LABAs increase the risk of asthma-related death. Physicians should only prescribe the drug for patients not adequately controlled on inhaled corticosteroids alone.
- Contraindications: Not indicated for acute bronchospasm or status asthmaticus. Contraindicated in patients with severe hypersensitivity to milk proteins.
- Adverse Reactions: Common reactions include upper respiratory tract infection, pharyngitis, and oral candidiasis. Long-term use may affect bone mineral density and growth velocity in pediatric patients.
- Drug Interactions: Strong CYP3A4 inhibitors are not recommended due to increased systemic corticosteroid effects.
Forward-Looking Statements: GSK cautions that actual results may differ materially from projections due to risks described in their 2014 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the publication of full VESTRI study results in a peer-reviewed forum as promised by management.
- Confirm the regulatory status of the 250/50mcg dose, which is noted as not currently licensed for paediatric asthma treatment in the US.
- Review the 2014 Form 20-F for detailed risk factors regarding the respiratory franchise and patent cliffs.
- Monitor for any FDA communications regarding the acceptance of the VESTRI data for label updates or continued market authorization.